Classified as a norepinephrine (noradrenaline) reuptake inhibitor,
atomoxetine is approved for use in children, adolescents,
and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants,[2][3] is not scheduled as a controlled substance and has proven in clinical trials to offer 24-hour coverage of symptoms associated with ADHD in adults and children.